1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
118(c) 115(c) 115(c) 113(c) 113.75(c) Last
125 739 258 828 200 601 130 079 124 177 Volume
+0.85% -2.54% 0.00% -1.74% +0.66% Change
More quotes
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 - - -
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 141 M 176 M 176 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 11
Free-Float 72,6%
More Financials
Company
Arix Bioscience plc is a United Kingdom-based venture capital company that is focused on investing in and building biotechnology companies around advances in life sciences. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. The Company's principal activity is to source, finance and develop healthcare and life science... 
More about the company
All news about ARIX BIOSCIENCE PLC
05/13Avantor Names Jonathan Peacock Chairman
MT
05/05TRANSCRIPT : Arix Bioscience plc, 2021 Earnings Call, May 05, 2022
CI
05/05Arix Bioscience plc Reports Earnings Results for the Full Year Ended December 31, 2021
CI
05/04Arix Bioscience Shareholder Acacia Research Lifts Stake To 21%
MT
05/04Acacia Research Reportedly Says It Doesn't Expect to Make Offer for Arix Bioscience, Bl..
MT
2021Sorriso Pharmaceuticals, Inc. announced that it has received $31 million in funding fro..
CI
2021Sorriso Pharmaceuticals, Inc. announced that it expects to receive $31 million in fundi..
CI
2021Arix Bioscience's Investee Raises $34 Million Via Oversubscribed Funding Round
MT
2021Depixus SAS announced that it has received €30.6 million in funding from Lansdowne..
CI
2021Arix Bioscience Unit Autolus Partners With Blackstone To Develop Cancer Therapies
MT
2021Arix Bioscience's Portfolio Firm Aura Biosciences Prices Nasdaq IPO
MT
2021ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
2021Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
2021Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
2021ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
More news
News in other languages on ARIX BIOSCIENCE PLC
05/13Avantor nomme Jonathan Peacock président
05/05Arix Bioscience plc annonce ses résultats pour l'année complète se terminant le 31 déce..
05/04Acacia Research, actionnaire d'Arix Bioscience, porte sa participation à 21%.
2021L'entreprise dans laquelle investit Arix Bioscience lève 34 millions de dollars via un ..
2021Autolus, unité d'Arix Bioscience, s'associe à Blackstone pour développer des thérapies ..
More news
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | ARIX | GB00BD045071 | MarketScreener
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 113,75 GBX
Average target price 256,00 GBX
Spread / Average Target 125%
Managers and Directors
Robert William Henry Lyne CEO, COO, Director & General Counsel
Nikki Edgar Head-Finance
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors